Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lanreotide (Primary) ; Pegvisomant
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
Most Recent Events
- 28 Mar 2014 New trial record
- 27 Aug 2009
- 15 Nov 2007